Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrclinonc.2017.27 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in moyamoya disease: pathogenesis, diagnosis, and therapeutic interventions.
MedComm (2020)
February 2025
Department of Neurosurgery Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing China.
Moyamoya disease (MMD) is a type of cerebrovascular disease characterized by occlusion of the distal end of the internal carotid artery and the formation of collateral blood vessels. Over the past 20 years, the landscape of research on MMD has significantly transformed. In this review, we provide insights into the pathogenesis, diagnosis, and therapeutic interventions in MMD.
View Article and Find Full Text PDFCharacterization for the Similarity Assessment Between the Proposed Biosimilar SB17 and Ustekinumab Reference Product Using State-of-the-Art Analytical Methods.
Drugs R D
January 2025
Quality Evaluation Team, Samsung Bioepis Co., Ltd, Incheon, South Korea.
Background: SB17 is being developed as a biosimilar to ustekinumab reference product (RP), a human monoclonal antibody (IgG1 kappa immunoglobulin) that binds to the common p40 subunit of cytokines interleukin (IL)-23 and IL-12. Binding to this subunit prevents interaction with their receptor, resulting in modulation in the immune system responses that play a key role in inflammatory disease.
Objective: The objective of this study was to demonstrate structural, physicochemical, and biological similarity between ustekinumab RP and SB17 using various state-of-the-art analytical methods.
Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [F]3F4AP.
J Nucl Med
January 2025
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts;
Spinal cord injuries (SCIs) often lead to lifelong disability. Among the various types of injuries, incomplete and discomplete injuries, where some axons remain intact, offer potential for recovery. However, demyelination of these spared axons can worsen disability.
View Article and Find Full Text PDFAntipsychotic Drug Prescribing in Children Previously Treated With Stimulants for ADHD: A Population-Based Longitudinal Study: La prescription d'antipsychotiques chez les enfants précédemment traités avec des stimulants pour le TDAH : une étude longitudinale basée sur la population.
Can J Psychiatry
January 2025
Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Objective: Stimulant drug treatment in preschool-age children for attention-deficit hyperactivity disorder (ADHD) as well as the concomitant use of antipsychotic drugs is largely unstudied in terms of longitudinal outcomes. We characterized longitudinal patterns of stimulant drug use in children diagnosed for ADHD and analyzed the mental health disorders leading to add-on therapy with antipsychotics.
Method: The study population comprised of children and adolescents (age: 0-19 years) in the province of British Columbia (BC), Canada, with at least one dispensing for any psychotropic drug between 1997 and 2017 ( = 144,825).
Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group.
JCO Glob Oncol
January 2025
Latin American Cooperative Oncology Group, Porto Alegre, Brazil.
Purpose: The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world.
Methods: In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!